Hello my dear ones! How’s everybody, how’s your heart if I can ask? February is the month we celebrate Valentine’s Day and many of us celebrated the 14th day with love, flowers and chocolate. We always bring our hearts together when we talk about this day because of the emotion or feeling we have towards our family, friends and someone special. But have you ever thought about your heart health these days?
A healthy heart is important if you want to live longer, but there are certain factors that can lead to heart failure, especially if you live with an unhealthy lifestyle. But the good news is that heart failure can be treated and even prevented. To spark conversation and awareness, AstraZeneca Philippines hosted a webinar to discuss the latest developments in heart failure. A panel of experts from the Philippines and around the world discussed how the approval of AstraZeneca’s dapagliflozin as a treatment option can make a difference in the lives of thousands of Filipinos. Learn more about this promising brand that “gives hope to the heart” below.
|Love your heart: hope for the failing heart
image from pexels.com
Heart failure, commonly called “pumapalyang puso”
- It affects thousands of Filipinos and approximately 64 million people worldwide, with half of patients dying within five years of diagnosis 1, 2, 3, 4.
- Patients with heart failure exhibit physical and emotional symptoms.
- This limits their activities resulting in a poor quality of life.
- Even at rest, some patients begin to experience shortness of breath and the sensation becomes heavier and heavier each day.
- Daily activities become more and more difficult, which makes them very vulnerable and hopeless.
- Many patients said they felt as if they were just waiting for death and felt guilty for placing a huge economic and emotional burden on their families.
According to Professor David Sim, president of the Heart Failure Society in Singapore, 9 million people in Southeast Asia suffer from heart failure with an overall death rate of 15% 5.6.
However, pharmacologic options for heart failure have increased over the past decade, and guideline-led drug therapy for heart failure cumulatively reduces mortality by 76%. 7 He noted, “The approval of the dapagliflozin for the treatment of HFrEF in the Philippines is a major breakthrough in the fight against the disease burden of heart failure. With the current standard of care, dapagliflozin will further contribute to reducing mortality, reducing hospitalizations for heart failure and above all improving the quality of life of patients with heart failure ”.
Professor Piotor Ponikowski of the Heart Failure Association of the European Society of Cardiology added that “heart failure is becoming a preventable and treatable disease, with drugs that allow patients to live longer and to live better outside the hospital. ” These current developments in treatment options bring hope to Filipinos diagnosed with heart failure. With the approval of AstraZeneca’s dapagliflozin as a treatment option for heart failure, Filipinos can now benefit from drugs that can alleviate the disease. In his presentation on Dapagliflozin and the Prevention of Adverse Outcome Trial in the DAPA HF Trial: A New Era in the Management of Heart Failure, Professor Piotr Ponikowski says: “Dapagliflozin has the ability to reduce mortality. , prevent hospitalization, improve clinical condition, functional capacity and quality of life. As such, to continue its efforts to improve the quality of care in the Philippines, AstraZeneca also announced a partnership with the Philippine Heart Association (PHA) to strengthen standardized care and improvement efforts. quality for heart failure to promote better awareness, management and options for patients.
Lotis Ramin, President of AstraZeneca Philippines, said: “During this COVID-19 pandemic, people with heart failure are among those at higher risk of complications. Good disease management will help improve the condition and avoid hospitalization. With the approval of dapagliflozin for use in adult heart failure patients with reduced ejection fraction, we are proud to give hope to the many Filipinos affected by heart failure. Through our partnership with PHA, we aim for a comprehensive cardiovascular care program ranging from preventing, promptly diagnosing, and managing symptoms of heart failure to making a meaningful difference in the lives of Filipinos. Do not be too long. Get an early diagnosis and start treatment. Start a conversation about heart failure with your doctor today.
- Is the first and only drug in the sodium-glucose transport protein inhibitor class 2 (SGLT2i) approved for the treatment of heart failure in adult patients with reduced ejection fraction (pumapalyang puso). 10,11,12 It is the only SGLT2i proven to significantly prevent cardiovascular death and death from other causes in these patients with heart failure.9
- This approval was based on the landmark Dapagliflozin and Prevention of Adverse-Results in Heart Failure Trial (DAPA HF) 1 trial.
- This is the first outcome trial with an SGLT2 inhibitor in the treatment of heart failure with reduced ejection fraction (HFrEF) .1 The results showed a 26% reduction in the occurrence of fatalities. Cardiovascular origin, hospitalization for heart failure (hHF) and emergency hospital Visit for heart failure (HF) with a 30% reduction in hHF. 1
- The significant reduction of 18% in cardiovascular mortality from dapagliflozin and 17% in mortality from other causes was observed only in the DAPA HF study. 9
- Dapagliflozin has offered an additional treatment option for patients with symptoms of heart failure who are at risk of death given the high death rate from the disease. The safety results in patients were consistent with the well-established safety profile of dapagliflozin in previous studies. It is consistent regardless of age, gender, severity of heart failure, diabetic status, and kidney function1. Dapagliflozin was well tolerated and adverse events rarely led to discontinuation of treatment1,8. In the Philippines, dapagliflozin is now approved for the treatment of heart failure with reduced ejection fraction in adult patients. Dapagliflozin is a prescription drug.10 Patients should not self-medicate and should consult their physician about their condition and treatment.
AstraZeneca PhilippineToday s hosted a panel titled Love Your Heart: Hope for the Failing Heart, with a discussion on the prevention and treatment of heart failure, which affects thousands of Filipinos each year. The group of medical experts presented facts about the risk and factors of heart failure and discussed how AstraZeneca’s latest medical innovation can now prevent and reduce the risk of heart failure.